Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9614.0600
Address
30 Flemington Road Bio21 Institute Parkville, Victoria (VIC) 3010
Description
Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. It offers a diagnostic blood test for screening for colorectal cancer under the ColoSTAT brand. The company was founded on June 1, 2017, and is headquartered in Parkville, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.04 - 0.37
Trade Value (12mth)
AU$7,024.00
1 week
8.06%
1 month
39.58%
YTD
-47.36%
1 year
-82.22%
All time high
2.04
EPS 3 yr Growth
-15.70%
EBITDA Margin
N/A
Operating Cashflow
-$6m
Free Cash Flow Return
-179.80%
ROIC
-200.90%
Interest Coverage
-2,671.80
Quick Ratio
1.60
Shares on Issue (Fully Dilluted)
240m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.45
Date | Announcements |
---|---|
30 August 24 |
Appendix 4E
×
Appendix 4E |
30 August 24 |
RHY Financial Report FY2024
×
RHY Financial Report FY2024 |
30 August 24 |
Appendix 4G
×
Appendix 4G |
28 August 24 |
Product and Market Update - Phase 2 Milestone
×
Product and Market Update - Phase 2 Milestone |
19 August 24 |
Notification of cessation of securities - RHY
×
Notification of cessation of securities - RHY |
14 August 24 |
FY2024 R&D Tax Incentive Loan Funding
×
FY2024 R&D Tax Incentive Loan Funding |
07 August 24 |
Change of Director's Interest Notice - Trevor Lockett
×
Change of Director's Interest Notice - Trevor Lockett |
07 August 24 |
Change of Director's Interest Notice - Lou Panaccio
×
Change of Director's Interest Notice - Lou Panaccio |
07 August 24 |
Change of Director's Interest Notice - Otto Buttula
×
Change of Director's Interest Notice - Otto Buttula |
01 August 24 |
Notification of cessation of securities - RHY
×
Notification of cessation of securities - RHY |
29 July 24 |
Jun 24 Quarterly Activities Report and Appendix 4C
×
Jun 24 Quarterly Activities Report and Appendix 4C |
12 July 24 |
Bioshares Biotech Summit Presentation
×
Bioshares Biotech Summit Presentation |
17 June 24 |
Change of Director's Interest Notice - Otto Buttula
×
Change of Director's Interest Notice - Otto Buttula |
17 June 24 |
Close of Shortfall Offer Pursuant to the Rights Issue
×
Close of Shortfall Offer Pursuant to the Rights Issue |
04 June 24 |
Change of Director's Interest - Otto Buttula
×
Change of Director's Interest - Otto Buttula |
28 May 24 |
Change of Director's Interest Notice - Otto Buttula
×
Change of Director's Interest Notice - Otto Buttula |
27 May 24 |
Notification regarding unquoted securities - RHY
×
Notification regarding unquoted securities - RHY |
27 May 24 |
Notification regarding unquoted securities - RHY
×
Notification regarding unquoted securities - RHY |
27 May 24 |
Notification regarding unquoted securities - RHY
×
Notification regarding unquoted securities - RHY |
27 May 24 |
Cancel - Notification regarding unquoted securities - RHY
×
Cancel - Notification regarding unquoted securities - RHY |
22 May 24 |
Otto Buttula to revert back to Non-Executive Chair
×
Otto Buttula to revert back to Non-Executive Chair |
07 May 24 |
Application for quotation of securities - RHY
×
Application for quotation of securities - RHY |
30 April 24 |
Mar24 Quarterly Activities Report and Appendix 4C
×
Mar24 Quarterly Activities Report and Appendix 4C |
24 April 24 |
Dr David Atkins appointed Chief Executive Officer of Rhythm
×
Dr David Atkins appointed Chief Executive Officer of Rhythm |
23 April 24 |
Rhythm Maintains ISO Certification
×
Rhythm Maintains ISO Certification |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.